C-R Pradeep
Overview
Explore the profile of C-R Pradeep including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pradeep C, Zeisel A, Kostler W, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, et al.
Oncogene
. 2011 Dec;
31(31):3569-83.
PMID: 22139081
The HER2/neu oncogene encodes a receptor-like tyrosine kinase whose overexpression in breast cancer predicts poor prognosis and resistance to conventional therapies. However, the mechanisms underlying aggressiveness of HER2 (human epidermal...
2.
Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep C, Kostler W, et al.
Oncogene
. 2011 Nov;
31(30):3505-15.
PMID: 22105361
Epidermal growth factor (EGF)-like growth factors control tumor progression as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the...
3.
Pradeep C, Kostler W, Lauriola M, Granit R, Zhang F, Jacob-Hirsch J, et al.
Oncogene
. 2011 Jul;
31(7):907-17.
PMID: 21743488
A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells...
4.
Emde A, Pradeep C, Ferraro D, Ben-Chetrit N, Sela M, Ribba B, et al.
Oncogene
. 2010 Dec;
30(14):1631-42.
PMID: 21132012
Monoclonal antibodies (mAbs) to HER2 are currently used to treat breast cancer, but low clinical efficacy, along with primary and acquired resistance to therapy, commonly limit clinical applications. We previously...